Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 2, 2008, Pages 63-74

  De Clercq, Erik ^a   Field, Hugh J ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

14 TERT BUTYL OXYCARBONYLAMINO 18 [4 FLUORO ISOINDOLINE 2 CARBOXYLATE] 2,15 DIOXO 3,16 DIAZATRICYCLO[14.3.0.04,6]NONADEC 7 ENE 4 [CYCLOPROPYLSULFONYL]CARBOXAMIDE; 4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; AMANTADINE; ANTIVIRUS AGENT; BETA DEXTRO 2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; CASTANOSPERMINE 6 BUTYRATE; CILUPREVIR; CYCLOSPORIN A DERIVATIVE; DEBIO 025; FAVIPIRAVIR; ICN 1229; ITMN 191; MP 424; N [3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL] 3 [2 (3 TERT BUTYLUREIDO) 3,3 DIMETHYL 1 OXOBUTYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXAMIDE; NITAZOXANIDE; NUCLEOSIDE DERIVATIVE; OSELTAMIVIR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PERAMIVIR; PIRODAVIR; PLECONARIL; PROTEINASE INHIBITOR; R 7128; RIBAVIRIN; RIBONUCLEOSIDE DERIVATIVE; RIMANTADINE; RO 5024048; RUPINTRIVIR; SIALIC ACID DERIVATIVE; T 705; TELAPREVIR; UNINDEXED DRUG; VIRAZIDE; VRT 111950; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMMON COLD; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN RHINOVIRUS; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LIVER TOXICITY; ORTHOMYXOVIRUS; PICORNAVIRUS; PRIORITY JOURNAL; RNA VIRUS; VIRUS INFECTION;

EID: 50349086200     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020801900204     Document Type: Article

References (64)

1. Aslam S, Musher DM. Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent. Future Microbiol 2007; 2:583-590.
2. Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008; 77:56-63.
3. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to Adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-257.
4. Davies WL, Grunert RR, Miles HB, et al. Antiviral activity of 1-adamantanamine (amantadine). Science 1964; 144:862-863.
5. Hayden FG, Aoki F. Amantadine, Rimantadine, and Related Agents. In Antimicrobial Therapy and Vaccines: Volume II: Antimicrobial Agents, 2nd edn. Edited by VL Yu, G Edwards, PS McKinnon, C Peloquin & GD Morse; pp 705-729.
6. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426:186-189.
7. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Shortterm antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127:1347-1355.
8. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005; 41:832-835.
9. Llinas Brunet M, Bailey M, Bolger G, et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J Med Chem 2004; 47:1605-1608.
10. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43:761-770.
11. Noser JA, Towers GJ, Sakuma R, Dumont JM, Collins MK, Ikeda Y. Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol 2006; 80:7769-7774.
12. Flisiak R, Dumont JM, Crabbé R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 2007; 16:1345-1354.
13. Villano S, Raible D, Harper D, Chandra P, Bazisotto L, Bichier G. Phase I evaluation of antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with different pegylated interferons in treatment-naive patients with chronic HCV. Hepatology 2007; 46 Suppl 1:815A.
14. Rajagopalan PTR, Stevens S, Stoycheva A, et al. Genotype coverage of the HCV/NS3/4A protease inhibitor ITMN-191 (R7227): biochemical data reveals potent inhibition and slow dissociation with genotype 1-6 proteases. Hepatology 2007; 46 Suppl 1:855A.
15. Whitby K, Taylor D, Patel D, Ahmed P, Tyms AS. Action of celgosivir (60-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother 2004; 15:141-151.
16. Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr Opin Investig Drugs 2007; 8:125-129.
17. Kim CU, Lew N, Williams MA, et al. Influenza neuraminidase inhibitors posessing a novel hydrophobic interaction ion the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119:681-690.
18. Hitchcock MJM. GS4104: A new orally administered anti-influenza drug candidate. International AntiViral News; 4:175.
19. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1:i5-i21.
20. Smee DF, Sidwell RW. Peramivir (BCX-1812, RWJ-270201): Potential new therapy for influenza. Expert Opin Investig Drugs 2002; 11:859-869.
21. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69:39-45.
22. Andries K, Dewindt B, Snoekes J, et al. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother 1992; 36:100-107.
23. Hayden FG, Hipskind GJ, Woerner DH, et al. Intranasal pirodavir (R 77975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995; 39:290-294.
24. Field HJ, Balzarini J, Kinchington D, De Clercq E. Current antiviral agents factfile: 1999-2000 update. Part I: Herpesviruses, hepatitis viruses and respiratory viruses. International AntiViral News 1999; 7:110-118.
25. Diana GD, Rudewicz P, Pevear DC, et al. Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem 1995; 38:1355-1371.
26. Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003; 36:1523-1532.
27. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds cause by rhinoviruses. Antimicrob Agents Chemother 2005; 49:4492-2299.
28. Klumpp K, Leveque V, Le Pogam S, et al. The novel nucleoside analog R1479 (4′-Azidocytidine) is a potent inhibitor of NS5B -dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006; 281:3793-3799.
29. Le Pogam S, Jiang W-R, Leveque V, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-Me-Cytidine or to R1479 show lack of cross resistance. Virology 2006; 351:349-359.
30. Leveque V, Le Pogam S, Kang H, et al. Antiviral potency of R1479, active compound derived in vivo from prodrug R1626, demonstrated across HCV genotypes 1-6 in NS5B recombinant enzymes and HCV replicons. 43rd Annual Meeting of the European Association for the Study of the Liver. 23-27 April 2008, Milan, Italy. Abstract 1298.
31. Le Pogam S, Seshaadri A, Kosaka A, et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008; 61:1205-1216.
32. Roberts S, Cooksley G, Dore G, et al. Results of a Phase 1B, multiple dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients. Hepatology 2006; 44 Suppl 1:692A.
33. Pockros PJ, Nelson D, Godofsky E, et al. Robust synergistic antiviral effect of R1626 in combination with Peginterferon alfa-2a (40KD), with or without ribavirin - interim analysis results of Phase 2a study. Hepatology 2007; 46 Suppl 1:311A.
34. Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007; 46 Suppl 1:862A.
35. Otto MJ, Robson R, Rodríguez CA, et al. Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside Polymerase Inhibitor for HCV, Following Single Ascending Oral Doses in Healthy Volunteers. 14th International Symposium on Hepatitis C Virus and Related Viruses. 9-13 September 2007 Glasgow, Scotland. Abstract 268.
36. Stuyver LJ, McBrayer TR, Tharnish PM, et al. Inhibition of hepatitis C replicon RNA synthesis by β-D-2′-deoxoy-2′-fluoro-2′-C-methylcytidine: A specific inhibitor of hepatitis C replication. Antivir Chem Chemother 2006; 17:79-87.
37. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-Ribofuranosyl-1,2,4,-triazole-3-carboxamide. Science 1972; 177:705-706.
38. Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med 1996; 150:942-947.
39. Leyssen P, De Clercq E, Neyts J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol 2006; 69:1461-1467.
40. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30:115-133.
41. Monto AS. Viral respiratory infections in the community: epidemiology, agents and interventions. Am J Med 1995; 99:24S-27S.
42. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother 1995; 29:299-310.
43. Dragovich PS, Prins TJ, Zhou R, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem 1999; 42:1213-1224.
44. Patick AK, Binford SL, Brothers MA, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999; 43:2444-2450.
45. Hayden FG, Turner RB, Gwaltney JM, et al. Phase II, randomized, double-blind, placebo-controlled studies of rupintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 2003; 47:3907-3916.
46. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007; 6:1001-1018.
47. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo. activities of anti-influenza compound T-705. Antimicrob Agents Chemother 2002; 46:977-981.
48. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49:981-986.
49. Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51:845-851.
50. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006; 50:899-909.
51. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46:640-648.
52. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alfa-2a inhibits wild-type and resistance genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-639.
53. Verloes R, Farha KA, van Vliet A, et al. Results of a phase I placebo-controlled trial in healthy volunteers to examine the safety, tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dose. Hepatology 2007; 46 Suppl 1:823A.
54. Simmen K, Lenz O, Lin T-I, et al. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor, TMC435350. Hepatology 2007; 46 Suppl 1:857A.
55. Afdhal N, Godofsky E, Dienstag J. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 2004; 40:726A.
56. Dieterich D, Lawitz E, Nguyen T, et al. Early clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naive patients with HCV-1 infection: first results from a phase IIb trial. J Hepatol 2006; 44 Suppl 2: S271,736A.
57. Coelmont L, Paeshuyse J, Windisch MP, De Clercq E, Bartenschlager R, Neyts J. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 2006; 50:3444-3446.
58. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DE In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005; 68:10-17.
59. Sidwell RW, Huffman JH, Barnard DL, Pifat DY. Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced phlebovirus infections. Antiviral Res 1988; 10:193-207.
60. Wu JZ, Larson G, Hong Z. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrob Agents Chemother 2004; 48:4006-4008.
61. Wu JZ, Lin CC, Hong Z. Ribavirin, viramidine, and adenosine deaminiase catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother 2003; 52:543-546.
62. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-423.
63. Hayden FG, Wightman K, Keene O, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874-880.
64. Hayden FG, Aoki F. Influenza Neraminidase Inhibitors (Oseltamivir and Zanamivr). In Antimicrobial Therapy and Vaccines: Volume II: Antimicrobial Agents, 2nd edn, Edited by VL Yu, G Edwards, PS McKinnon, C Peloquin & GD Morse; pages 773-789.